Adebrelimab and Chemoradiotherapy in High-risk LANPC

This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).

Trial Details

NCT ID

NCT06349889

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

Adebrelimab

Locations (sample)

Xiamen, Fujian, China|24.47979,118.08187
Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25
Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

Patients with histologically confirmed nasopharyngeal carcinoma.
Tumor staged as IVA+T3N2M0 (AJCC 8th).
Eastern Cooperative Oncology Group performance status ≤1.
Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →